Clearmind Medicine公司近日宣布，已正式向欧洲专利局提交针对新型迷幻化合物的专利申请，该系列化合物主要用于创伤后应激障碍（PTSD）的临床治疗。此次专利布局标志着公司在精神健康治疗领域的创新研发取得重要进展。
新型迷幻化合物通过调节神经递质系统，展现出对创伤记忆再巩固过程的独特干预能力。临床前研究表明，这类化合物能有效缓解PTSD核心症状，包括过度警觉、回避行为和侵入性记忆，同时具备较传统药物更佳的安全性特征。
此次欧洲专利申请的提交，是继北美地区知识产权保护后，公司全球战略部署的关键一环。若获得批准，将为企业构建覆盖主要医药市场的专利护城河，为后续商业化奠定坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.